The stock price of TuHURA Biosciences Inc (NASDAQ: HURA) has dropped by -11.23 compared to previous close of 6.68. Despite this, the company has seen a gain of 7.04% in its stock price over the last five trading days. accesswire.com reported 2024-11-25 that IFx-2.0, a first-in-class innate immune response agonist, entering single Phase 3 accelerated approval registration trial in first half of 2025 for first line treatment of Merkel Cell Carcinoma (MCC) under Special Protocol Assessment (SPA) agreement with U.S. Food and Drug Administration (FDA) Entered into a non-binding letter of intent with Kineta regarding a potential transaction in which TuHURA would acquire the rights to KVA12123 expanding its pipeline with a Phase 2 ready, novel VISTA inhibiting antibody Advancing IFx-3.0, the first systemically administered tumor-targeted mRNA innate immune response agonist for aggressive B Cell Lymphoma Early discovery programs designing first-in-class tumor microenvironment modulating bi-specific antibody drug conjugates (ADCs) or peptide drug conjugates (PDCs) targeting Myeloid Derived Suppressor Cells (MDSCs) Company expands leadership team with key clinical and regulatory appointments to drive strategy and operational execution TAMPA, FL / ACCESSWIRE / November 25, 2024 / TuHURA Biosciences, Inc. (Nasdaq:HURA) (“TuHURA” or the “Company”), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, today provided a business update and outlined upcoming targeted milestones. “We have made significant progress toward accomplishing our 2024 corporate objectives, including reaching a Special Protocol Assessment agreement with the FDA by working with the Oncology Center of Excellence (OCE) and FDA’s Project Front Runner initiative for a novel Phase 3 trial design for IFx-2.0 under the FDA’s accelerated approval pathway.
Is It Worth Investing in TuHURA Biosciences Inc (NASDAQ: HURA) Right Now?
Moreover, the 36-month beta value for HURA is 0.85. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for HURA is 23.78M and currently, short sellers hold a 0.58% of that float. On December 10, 2024, HURA’s average trading volume was 235.02K shares.
HURA’s Market Performance
HURA stock saw an increase of 7.04% in the past week, with a monthly gain of 12.52% and a quarterly increase of -2.06%. The volatility ratio for the week is 14.60%, and the volatility levels for the last 30 days are 17.72% for TuHURA Biosciences Inc (HURA). The simple moving average for the past 20 days is 23.61% for HURA’s stock, with a -2.79% simple moving average for the past 200 days.
Analysts’ Opinion of HURA
Many brokerage firms have already submitted their reports for HURA stocks, with Maxim Group repeating the rating for HURA by listing it as a “Buy.” The predicted price for HURA in the upcoming period, according to Maxim Group is $15 based on the research report published on November 05, 2024 of the current year 2024.
HURA Trading at 6.63% from the 50-Day Moving Average
After a stumble in the market that brought HURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -59.37% of loss for the given period.
Volatility was left at 17.72%, however, over the last 30 days, the volatility rate increased by 14.60%, as shares surge +20.53% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -17.15% lower at present.
During the last 5 trading sessions, HURA rose by +7.04%, which changed the moving average for the period of 200-days by +85.78% in comparison to the 20-day moving average, which settled at $4.80. In addition, TuHURA Biosciences Inc saw -0.10% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for HURA
The total capital return value is set at -4.16. Equity return is now at value -370.77, with -163.44 for asset returns.
Currently, EBITDA for the company is -29.12 million with net debt to EBITDA at 0.39. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.45.
Conclusion
To wrap up, the performance of TuHURA Biosciences Inc (HURA) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
